We use cookies to understand how visitors search for and consume the information we provide, so that we can improve their experience. By browsing this website, you indicate your acceptance of the use of such cookies
Accept
Read more
Direct accesses
Go to main menu
Go to main content
Menu
Search the site
Contact
Careers
You are viewing the website in English
en
fr
Search the site
Who
we are
Company
Leadership
Collaborations
Our products
& pipeline
Diseases we target
GS010 for LHON
GS030 for Retinitis Pigmentosa
GS030 for Geographic Atrophy in Dry-AMD
Our
technologies
Technologies we are applying
Gene Therapy
Mitochondrial Targeting Sequence (MTS)
Optogenetics
Investors
& media
Company Overview
Press releases
Events & presentations
News and press coverage
Stock information
Governance
Documentation
Press releases
Home
>
Investors & media
>
Press releases
Year
All
2021
2020
2019
2018
2017
2016
2015
2014
2013
News type
All
Regulatory
Clinical
Conferences
Corporate
Finance
General Meeting
Product candidates
Science & Technology
Other
Subject
All
Company and personnel
GS010 - LUMEVOQ
GS030
Technologies
Other
08 April 2021
GenSight Biologics Announces the Filing of its 2020 Universal Registration Document
08 April 2021
Annual General Meeting on April 29, 2021
26 March 2021
GenSight Biologics successfully raises €30 million in an oversubscribed private placement with European and US institutional investors
25 March 2021
GenSight Biologics launches a reserved offering of c. €25 million by means of an accelerated bookbuilding process
10 March 2021
GenSight Biologics Reports Full Year 2020 Financial Results and provides an Outlook on 2021
15 February 2021
GenSight Biologics Announces Publication of Results from LUMEVOQ® Phase I/IIa Clinical Trial REVEAL in BioDrugs
04 February 2021
GenSight Biologics Announces the Publication in Communications Biology of the Proof-of-Concept for GS030-Drug Product in Non Human Primates
19 January 2021
GenSight Biologics Reports Cash Position as of December 31, 2020 and Provides Operational Update
18 January 2021
GenSight Biologics Announces its 2021 Financial Calendar
13 January 2021
GenSight Biologics Announces Publication of Results from LUMEVOQ® RESCUE Pivotal Phase III Trial in AAO journal Ophthalmology®
1
2
3
4
5
6
…
13
View next 9 articles
Go back to the page of the page